Mayne Pharma Group Ltd (fra:HG6) Share Price

Company Profile

Business description
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercialising branded women's health and dermatology pharmaceuticals, offering patients better, safer, and more accessible medicines. The Company has a product development and manufacturing facility in Salisbury, Australia, with expertise in the formulation of complex oral and topical dose forms, including modified-release products and poorly soluble compounds. Its segments are Women's Health, Dermatology and International. The Women's Health segment generates maximum revenue and distributes branded products in the US, including NEXTSTELLIS, ANNOVERA, IMVEXXY, and BIJUVA. The Company generates maximum revenue from the United States.
Contact
1538 Main North Road
Salisbury South
SalisburySA5106
AUS
T: +61 882092666
https://www.maynepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Distribution
Fiscal Year End
Employees
470

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,782.82	28.44	-0.36%
DAX 40	25,181.65	190.10	-0.75%
Dow JONES (US)	52,215.16	652.82	-1.23%
FTSE 100	10,690.36	34.67	-0.32%
HKSE	23,093.37	158.69	0.69%
NASDAQ	25,955.34	53.52	-0.21%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,623.68	39.75	-0.52%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%